All In Biotech

NDA 020298 · Mylan

Aloprim

Allopurinol Sodium · Injection

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 17, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

209

51 Phase 3, 13 recruiting

FAERS reports

157,748

129,258 serious, 22,111 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 18, 2022.

ALOPRIM is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. ALOPRIM is a xanthine oxidase inhibitor indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. ( 1 )

Mechanism: Allopurinol is a structural analogue of the natural purine base, hypoxanthine. Allopurinol and its oxypurinol metabolite inhibitor xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol does not disrupt the biosynthesis of purines. The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 17, 1996 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • ALOPRIM · ALLOPURINOL SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Allopurinol" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea8,831
  • fatigue8,385
  • dyspnoea8,016
  • nausea7,397
  • death6,985
  • acute kidney injury6,871
  • off label use6,806
  • pyrexia6,125
  • pneumonia5,754
  • asthenia5,712
  • anaemia5,511
  • drug ineffective5,240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,482
20052,097
20062,079
20071,811
20082,228
20092,744
20103,359
20114,397
20125,350
20135,159
20145,525
20158,242
20169,190
20179,476
201812,941
201913,166
202012,835
202111,186
202210,731
20239,249
20248,954
20259,066
20266,469

Recalls

1 FDA enforcement reports for this application.

  • May 5, 2020 · Class II · Terminated

    Discoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of Solution.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 805 on PubMed

Sponsor: Mylan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.